PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:
A61K 38/21, 38/17, C07K 14/555, 14/715, 19/00, C12N 15/12, 5/10

A1

(11) International Publication Number: **WO 99/32141**

(43) International Publication Date: 1 July 1999 (01.07.99)

(21) International Application Number: PCT/US98/26926

(22) International Filing Date: 18 December 1998 (18.12.98)

(30) Priority Data:
60/068,295 19 December 1997 (19.12.97) US

(71) Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL]; 14 John B. Gorsiraweg, Curacao (AN).

(71) Applicant *(for GD only)*: MCINNIS, Patricia, G. [US/US]; Apt. #203, 2325 42nd Street, N.W., Washington, DC 20007 (US).


(72) Inventors: TEPPER, Mark; 60 Eagle Drive, Canton, MA 02021 (US). CUNNINGHAM, Mark; Apartment 606, 103 Fox Road, Waltham, MA 02451 (US). SHERRIS, David; 37 Nellian Crescent, Jamaican Plain, MA 02130 (US). EL TAYAR, Nabil; 143 Gerald Road, Milton, MA 02186 (US). MCKENNA, Sean; 679 Lincoln Street, Ducksberry, MA 02332 (US).

(74) Agent: BROWDY, Roger, L.; Browdy and Neimark, P.L.L.C., Suite 300, 419 Seventh Street N.W., Washington, DC 20004 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: IFNAR2/IFN COMPLEX



(57) Abstract

The *in vivo* effect of Type I interferon (IFN) can be prolonged by administering the interferon in the form of a complex with an IFN binding chain of the human interferon α/β receptor (IFNAR). Such a complex also improves the stability of the IFN and enhances the potency of the IFN. The complex may be a non-covalent complex or one in which the IFN and the IFNAR are bound by a covalent bond or a peptide. When bound by a peptide bond in the form of a fusion protein, the IFN may be separated from the IFNAR by means of a peptide linker. Such a fusion protein may be produced by recombinant DNA technology. Storing IFN in the form of such a complex improves the storage life of the IFN and permits storage under milder conditions than would otherwise be possible.